AdaptHealth Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AdaptHealth in the last year. There are currently 1 sell rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AdaptHealth stock.
View analyst ratings for AdaptHealth or view top-rated stocks.

Wall Street analysts have given AdaptHealth a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AdaptHealth wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

AdaptHealth saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 5,470,000 shares, an increase of 18.1% from the July 29th total of 4,630,000 shares. Based on an average daily trading volume, of 962,200 shares, the days-to-cover ratio is currently 5.7 days. Currently, 5.9% of the company's shares are sold short.
View AdaptHealth's Short Interest.

AdaptHealth is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for AdaptHealth.

AdaptHealth Corp. (NASDAQ:AHCO) announced its quarterly earnings results on Wednesday, August, 4th. The company reported $0.12 EPS for the quarter, missing the Zacks' consensus estimate of $0.29 by $0.17. The business had revenue of $617 million for the quarter, compared to analysts' expectations of $574.03 million. AdaptHealth had a net margin of 2.40% and a trailing twelve-month return on equity of 8.18%. The company's revenue was up 165.8% compared to the same quarter last year.
View AdaptHealth's earnings history.

AdaptHealth's stock was trading at $15.82 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AHCO shares have increased by 51.8% and is now trading at $24.01.
View which stocks have been most impacted by COVID-19.

AdaptHealth updated its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.38 billion-$2.48 billion, compared to the consensus revenue estimate of $2.30 billion.

10 brokerages have issued 1 year target prices for AdaptHealth's shares. Their forecasts range from $36.00 to $50.00. On average, they expect AdaptHealth's stock price to reach $45.17 in the next twelve months. This suggests a possible upside of 88.1% from the stock's current price.
View analysts' price targets for AdaptHealth or view top-rated stocks among Wall Street analysts.

Some companies that are related to AdaptHealth include Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), Option Care Health (OPCH), Signify Health (SGFY), Aveanna Healthcare (AVAH), Addus HomeCare (ADUS), Apria (APR), APR Energy (APR), Cancer Treatment (CTHZ) and New York Health Care (BBAL).
View all of AHCO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AdaptHealth investors own include Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), Advance Auto Parts (AAP), American International Group (AIG), Biogen (BIIB), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY), Caterpillar (CAT), Cisco Systems (CSCO) and CVS Health (CVS).

AdaptHealth trades on the NASDAQ under the ticker symbol "AHCO."

AdaptHealth's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.33%), BlackRock Inc. (4.32%), Silvercrest Asset Management Group LLC (1.97%), Geode Capital Management LLC (1.24%), State Street Corp (1.18%) and Morgan Stanley (0.73%). Company insiders that own AdaptHealth stock include Alan G Quasha, Assured Investment Management, Dale B Wolf, Ronald T Mcdaniel, Shaw Rietkerk and Stephen P Griggs.
View institutional ownership trends for AdaptHealth.

AHCO stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Principal Financial Group Inc., Vanguard Group Inc., JPMorgan Chase & Co., FMR LLC, Royal Bank of Canada, Renaissance Technologies LLC, and Maven Securities LTD. Company insiders that have sold AdaptHealth company stock in the last year include Assured Investment Management, Ronald T Mcdaniel, and Shaw Rietkerk.
View insider buying and selling activity for AdaptHealth or view top insider-selling stocks.

AHCO stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Maverick Capital Ltd., Armistice Capital LLC, Kennedy Capital Management Inc., BlackRock Inc., MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income, and Silvercrest Asset Management Group LLC. Company insiders that have bought AdaptHealth stock in the last two years include Alan G Quasha, Dale B Wolf, and Stephen P Griggs.
View insider buying and selling activity for AdaptHealth or or view top insider-buying stocks.

Shares of AHCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AHCO stock can currently be purchased for approximately $24.01.

AdaptHealth has a market capitalization of $3.14 billion and generates $1.06 billion in revenue each year. The company earns $-64,480,000.00 in net income (profit) each year or $0.43 on an earnings per share basis.

AdaptHealth employs 4,700 workers across the globe.

The official website for AdaptHealth is www.adapthealth.com.

AdaptHealth is headquartered at 220 West Germantown Pike Suite 250, Plymouth Meeting PA, 19462.

AdaptHealth's mailing address is 220 West Germantown Pike Suite 250, Plymouth Meeting PA, 19462. The company can be reached via phone at (610) 630-6357 or via email at [email protected].